Novavax Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
2025.11.20 22:28
portai
I'm PortAI, I can summarize articles.

Novavax Inc.'s stock fell 1.89% to $6.22 on Thursday, marking its seventh consecutive day of losses. The stock is 46.15% below its 52-week high. In comparison, Johnson & Johnson rose 0.28%, while Pfizer and Merck fell 1.93% and 0.08%, respectively. Trading volume was below the 50-day average. The NASDAQ and Dow Jones also experienced declines.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Novavax Inc. (NVAX) slipped 1.89% to $6.22 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 2.15% to 22,078.05 and Dow Jones Industrial Average falling 0.84% to 45,752.26. This was the stock's seventh consecutive day of losses. Novavax Inc. closed 46.15% below its 52-week high of $11.55, which the company achieved on January 7th. The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.28% to $203.07, Pfizer Inc. (PFE) fell 1.93% to $24.40, and Merck & Co. Inc. (MRK) fell 0.08% to $94.97. Trading volume (3.9 M) remained 632,522 below its 50-day average volume of 4.5 M. Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-20-25 1728ET
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.